Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia: A Merged Analysis from the Pediatric Real-World CAR Consortium (PRWCC) and Pediatric Health Information System (PHIS)
Prakash Satwani(Pediatrics and Genetics), Liora M. Schultz(Stanford Medicine), Michael R. Verneris(NHS Blood and Transplant), Samuel John(Southwestern Medical Center), Jeremy D. Goldhaber‐Fiebert(Stanford Health Care), Vanessa A. Fabrizio(Children's Hospital Colorado), Muna Qayed(Emory University), John K. Lin(Harvard Global Health Institute), Danielle Novetsky Friedman(National Coalition for Cancer Survivorship), Lena E. Winestone(University of California, San Francisco), Christina Baggott(Palo Alto University), Zhezhen Jin, Karen Chao(Stratford University), Amy K. Keating(Boston Children's Hospital), Matt Hall(Child Health Corporation of America), M. Pilar López-García(Universitat de València), Susanne H.C. Baumeister(Dana-Farber Cancer Institute), Snehit Prabhu(Stanford University), Amy Moskop(Medical College of Wisconsin), Julie‐An Talano(Dana-Farber Cancer Institute), Theodore W. Laetsch(Children's Hospital of Philadelphia), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Doug Myers(Children's Mercy Hospital), Khanh Nguyen(Stanford University), Rachel Phelan(Children's Hospital of Wisconsin), Holly Pacenta(Children's Hospital Colorado), Christine L. Phillips(Cincinnati Children's Hospital Medical Center), Erin Hall(Children's Mercy Hospital)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National, regional, and global trends in adult overweight and obesity prevalences
|Population Health Metrics|2012|929